BioCentury | Nov 19, 2020
Finance

Nov. 18 Quick Takes: Venture rounds for Elevation, Pharvaris as Kodiak follow-on brings in $560M; plus AbCellera takes out Trianni for $90M and more

Elevation raises $65M series B, names Leland CEOElevation Oncology Inc. raised $65 million in a series B round and promoted founder Shawn Leland from CBO to CEO. The venture round was led by venBio Partners and Cormorant...
BioCentury | Nov 19, 2020
Finance

With $4.6B fund to spend, Blackstone branching beyond Clarus’ ‘bread and butter’ risk-sharing deals

Two years after Clarus’ acquisition by Blackstone, the life sciences investor is taking advantage of its parent company’s scale to stretch beyond its initial sweet spot. The firm that specialized in risk-sharing deals is now...
BioCentury | Nov 14, 2020
Deals

Innovation in a hurry: China biotechs see a fast track to global stage – survey

The Chinese biopharma landscape in five years will see a majority of the money magnet companies commanding innovation, with first-in-class targets filling their pipelines and innovative biologics outpacing...
BioCentury | Oct 31, 2020
Distillery Therapeutics

Blocking ROR2 for osteoarthritis

DISEASE CATEGORY: Musculoskeletal INDICATION: Osteoarthritis Inhibiting the tyrosine protein kinase receptor ROR2 could treat osteoarthritis. Expression levels of the ROR2 ligand WNT5A were higher in human osteoarthritic cartilage than in healthy cartilage. In a mouse fibroblast...
BioCentury | Oct 30, 2020
Distillery Therapeutics

Targeting water channel AQP1 for hypertrophic cardiomyopathy

DISEASE CATEGORY: Cardiovascular INDICATION: Cardiomyopathy Inhibiting AQP1, a water channel expressed in cardiac and vascular tissues, could treat hypertrophic cardiomyopathy. Among 26 patients with aortic stenosis, high AQP1 mRNA expression in cardiac biopsies was associated with...
BioCentury | Oct 30, 2020
Distillery Therapeutics

KSP as a neuroblastoma target

DISEASE CATEGORY: Cancer INDICATION: Neuroendocrine tumors Inhibiting the mitotic kinesin KSP could treat neuroblastoma, a pediatric sympathetic nervous system malignancy. In neuroblastoma patients, high KSP expression in tumors was associated with high-risk neuroblastoma, advanced tumor...
BioCentury | Oct 29, 2020
Finance

Oct. 28 Quick Takes: Mirati raises $800M on KRAS data; BMS-insitro, Novartis-Molecular Partners, Genecast, Gracell, PureTech, Cerevel, Biodesix

Adagrasib readout helps Mirati build war chestResponse rate data in the closely-watched KRAS inhibitor race helped Mirati Therapeutics Inc. (NASDAQ:MRTX) raise $800 million in a follow-on via the sale of 4 million shares at $202...
BioCentury | Oct 2, 2020
Distillery Therapeutics

Blocking a lipid hydrolase for liver fibrosis

DISEASE CATEGORY: Hepatic INDICATION: Liver fibrosis; non-alcoholic steatohepatitis (NASH) Inhibiting ASAH1, an enzyme that hydrolyzes ceramide, could treat liver fibrosis. In patients with chronic HCV infection, levels of ASAH1 in hepatic stellate cells were higher in...
BioCentury | Sep 29, 2020
Distillery Therapeutics

Repeat expansion-targeting antisense oligo for ALS and frontotemporal dementia

DISEASE CATEGORY: Neurology INDICATION: Amyotrophic lateral sclerosis (ALS); frontotemporal dementia Mayo Clinic and Perelman School of Medicine researchers showed that an antisense oligonucleotide...
BioCentury | Aug 28, 2020
Distillery Therapeutics

Preventing thrombosis using nanoparticles loaded with anti-G protein peptides

DISEASE CATEGORY: Cardiovascular INDICATION: Ischemia/reperfusion injury Nanoparticles loaded with a peptide inhibitor of GNA13, a G protein subunit, could treat cardiac ischemia/reperfusion injury. The...
Items per page:
1 - 10 of 4198